All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Astral Systems raises £23m Series A to scale multi-state nuclear fusion technology for medical radioisotopes

By

Kirstie Pickering

13d ago· 2 min readenNews

Summary

Bristol-based deep tech firm Astral Systems has raised £23m in Series A funding led by Mercia Ventures. The company has developed and commercialised a multi-state fusion technology, a novel form of nuclear fusion aimed at addressing fragile supply chains and potential global shortages of medical radioisotopes used in cancer diagnosis and treatment. The funding will support the development of a new facility at the former Berkeley Power Station, with plans to run multiple next-generation compact fusion reactors at full capacity by the end of 2026.

Source

bskyAstral Systems raises £23m Series A to scale multi-state nuclear fusion technology for medical radioisotopesuktech.news

Key quotes

· 2 pulled
Astral Systems has created and commercialised a multi-state fusion technology – a new type of nuclear fusion that could tackle the fragile supply chain and potential global shortages of medical radioisotopes that impact cancer diagnosis and treatments.
With the Series A capital and its new facility being developed at the former Berkeley Power Station, the firm intends to run multiple next-generation compact fusion reactors at full capacity by the end of 2026.
Snippet from the RSS feed
Bristol-based deep tech firm Astral Systems has secured a £23m Series A round led by Mercia Ventures.  Astral Systems has created and commercialised a Bristol-based deep tech firm Astral Systems has secured a £23m Series A round led by Mercia Ventures.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.